According to the 2025 Aon Global Risk Management Survey, risk convergence is accelerating across highly regulated sectors such as life sciences:
- Cyber attack or data breach remains the #1 global business risk.
- Technology disruption continues to climb risk rankings as digital systems become embedded across operations.
- Geopolitical volatility is rising, reflecting global supply chain exposure and regulatory fragmentation.
- Artificial intelligence (AI) has entered the top ten future risks for the first time.
For life sciences businesses, these risks do not sit in isolation. A cyber breach can trigger regulatory investigation. A supply chain disruption can delay clinical trials. An operational failure can compromise patient safety or product integrity.
Resilience therefore requires a joined-up approach across cyber security, regulatory compliance, operational continuity, and governance.
Where regulatory, operational, and cyber risk intersect
Life sciences organisations face overlapping exposures, including:
- Strict regulatory oversight from authorities such as the MHRA and EMA
- Intellectual property protection and trade secret security
- Complex global supply chains
- Good Manufacturing Practice (GMP) and quality control obligations
- Clinical trial integrity and data governance
A cyber incident affecting trial data or manufacturing systems can result in:
- Regulatory penalties or delayed approvals
- Product recalls or halted production
- Reputational damage and investor concern
As digital tools and connected technologies become central to laboratories, production facilities, and distribution networks, cyber resilience is inseparable from operational and regulatory resilience.
Yet industry-wide research shows that only a minority of organisations comprehensively quantify exposure to their top strategic risks. This gap presents a challenge in a sector where compliance failures can have material financial and reputational consequences.
AI innovation with governance
Artificial intelligence is transforming the life sciences sector:
- Accelerating drug discovery and molecular modelling
- Optimising clinical trial design and patient recruitment
- Enhancing pharmacovigilance and real-world evidence analysis
- Improving manufacturing efficiency through predictive analytics
AI adoption supports innovation and competitive advantage. However, regulatory frameworks demand transparency, traceability, and explainability in algorithm-driven decisions.
Without structured governance, AI can introduce:
- Data integrity risks
- Regulatory non-compliance
- Ethical and bias concerns
- Cyber vulnerabilities within connected systems
Embedding governance alongside AI implementation ensures that innovation strengthens resilience rather than undermines it. Boards and leadership teams must align digital strategy with risk oversight to protect research pipelines and market approvals.
Supply chain and geopolitical exposure
Life sciences supply chains are global and highly specialised. Raw materials, active pharmaceutical ingredients, and manufacturing capabilities often span multiple jurisdictions.
Geopolitical tensions, trade restrictions, or regulatory divergence can:
- Delay clinical programmes
- Disrupt manufacturing inputs
- Increase costs and extend time to market
Strategic resilience requires supply chain mapping, diversification planning, and contractual risk transfer mechanisms to protect continuity.
Claims, continuity, and reputation
In life sciences, disruption extends beyond financial loss. It can affect patients, healthcare providers, and public trust.
When incidents occur – whether cyber breaches, manufacturing interruptions, or product liability issues – claims handling becomes a critical moment of truth.
Effective claims management supports:
- Faster operational recovery
- Clear regulatory engagement
- Protection of brand and investor confidence
- Reduced long-term financial impact
Transparent communication and structured response processes can significantly reduce the reputational damage associated with disruption.
Designing resilience into life sciences strategy
Resilience in life sciences should be proactive and embedded across the organisation. Key actions include:
- Board-level risk integration – Align regulatory, cyber, and operational oversight.
- Cyber and data governance – Protect intellectual property and clinical data.
- AI governance frameworks – Ensure explainability, compliance, and transparency.
- Supply chain resilience planning – Map dependencies and develop contingency strategies.
- Insurance alignment – Structure commercial insurance and cyber coverage to support rapid recovery and regulatory engagement.
By integrating these disciplines, life sciences businesses can innovate confidently while protecting long-term enterprise value.
Why partner with NFP?
NFP works with life sciences businesses to align commercial insurance, cyber protection, claims expertise, and organisational resilience with regulatory and innovation demands.
Our support spans:
- Cyber risk assessment and protection
- Regulatory-aligned insurance strategies
- Claims management expertise
- Leadership development and governance alignment
- Operational continuity planning